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The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has
dramatically improved over the last decade; however, patients with visceral metastases
are still faced with poor outcomes. Phosphatase and tensin homolog (PTEN) loss is
observed in 40%–60% of mCRPC patients and is also associated with a poor prognosis.
Several PI3K/AKT/mTOR pathway inhibitors have been studied, with disappointing anti-
tumor activity. Here, we present a case of a patient with heavily treated mCRPC who had a
modest tumor response to concurrent carboplatin, abiraterone acetate/prednisone, and
liver-directed radiation therapy. We discuss the potential rationale supporting the use of
this combination therapy and its safety in mCRPC. While the underlying basic mechanism
of our patient’s anti-tumor response remains uncertain, we suggest that further
prospective studies are warranted to evaluate whether this combination therapy is
effective in this population of patients with pre-treated mCRPC and PTEN loss.
Keywords: metastatic castration refractory prostate cancer, PI3K/AKT pathway, carboplatin, abiraterone acetate,
ATM/Chk2/p53 signal pathway
INTRODUCTION
Visceral metastases in men with metastatic castration-resistant prostate cancer (mCRPC) occur at a
very late stage of disease. One retrospective study showed that the rate of radiologically detected
visceral metastases before death from prostate cancer was 32% (1). In the vast majority of patients
with visceral metastases, there are also detectable metastases at other sites such as bone and regional
lymph nodes (1). The site of metastases impacts the expected survival of a patient. A prior meta-
analysis showed that the poorest overall survival is seen in men with liver metastases (13.5 months)
followed by lung metastases (19.4 months), non-visceral bone metastases (21.3 months), and lymph
node-only metastases (31.6 months) (2).
The treatment landscape of mCRPC has dramatically improved over the last decade. The
development of potent androgen synthesis and receptor inhibitors (3, 4); chemotherapy with taxanes
alone or in combination with a platinum (5–8); poly (ADP-ribose) polymerase (PARP) inhibitors in
patients who carry DNA homologous recombination repair gene-mutations (9); immunotherapy in
men with high microsatellite instability (10); and prostate-specific membrane antigen (PSMA) targeted
radiopharmaceutical agents (11) have significantly prolonged overall survival and progression-free
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survival in mCRPC. Still, the disease is incurable and patients with
visceral metastases have a limited expected survival.
Loss of the tumor suppressor gene phosphatase and tensin
homolog (PTEN) is identified in 15%–20% of primary prostate
tumor samples. Upon progression to castrate-resistant disease, the
incidence increases to 40%–60% (12). Loss of function of PTEN
leads to an activation of the PI3K/AKT/mTOR pathway
precipitating cell proliferation, growth, and survival. PTEN loss
is associated with a poor prognosis and is an independent
prognostic indicator of prostate-cancer-specific death (12).
While several PI3K/AKT/mTOR pathway inhibitors have been
studied in mCRPC, the majority of outcomes have been
disappointing, with no significant anti-neoplastic activity (13–
19). However, early-phase studies show that ipatasertib, a new
oral small-molecule inhibitor of AKT (protein kinase B), has
promising anti-tumor activity when combined with novel
hormonal agents; the activity appears to be significantly
increased in mCRPC patients with PTEN loss (20). A Phase III
randomized study of ipatasertib plus abiraterone is currently
ongoing (21). Currently, treatment of mCRPC patients with
PTEN loss is challenging.
Here, we present the case of a patient with PTEN loss
castration-resistant prostate cancer with liver-only metastases
who failed multiple lines of treatment but demonstrated some
modest response to the combination of abiraterone acetate/
prednisone plus carboplatin and liver-directed radiation therapy.
CASE PRESENTATION
A 62-year-old gentleman with a family history of prostate cancer
and a personal history of stage II chronic lymphocytic leukemia
(CLL) under observation (not required any treatment) and a right
nephrectomy for stage I clear cell renal cell carcinoma (not
required any systemic treatment) was diagnosed with a
localized, high-risk prostate adenocarcinoma. His pre-surgery
prostatic specific antigen (PSA) was 19.7 ng/ml, and he had a
Gleason score of 4 + 5 = 9 in all prostate biopsy cores. He
underwent a radical prostatectomy with bilateral pelvic
lymphadenectomy in September 2016. Final pathology
confirmed prostate adenocarcinoma with a Gleason score of 4 +
5 = 9 with invasion of periprostatic fat and the seminal vesicle as
well as perineural invasion: pT3bN0. The pathology also revealed
positive surgical margins. Post-surgery PSA was 2.39 ng/ml. He
received bicalutamide and androgen deprivation therapy (ADT)
with leuprolide for 6 months from his local urologist but did not
receive salvage radiation. His PSA became undetectable with
ADT. Germline genetic testing was performed using the Ambry
CancerNext® test and was negative.
The patient presented to our medical oncology clinic in January
2020 with a 2-month history of lower abdominal pain, anal spasms,
constipation, and significant lower urinary tract symptoms with a
severe International Prostate Symptom Score (IPSS) of 33. He denied
loss of appetite and his weight had been maintained. His PSA had
risen to 2.3 in December 2019 in a previous record, but at our initial
visit, it was elevated to 11.70 ng/ml and further elevated to 41.78 ng/
ml within 4 weeks. A computerized tomography (CT) scan of his
chest and abdomen and pelvis demonstrated numerous liver lesions
and extensive sub-centimeter supraclavicular, mediastinal, and
bilateral axillary lymphadenopathy. A nuclear bone scan was
negative for bony metastases. Subsequently, a whole-body positron
emission tomography/CT scan was performed to evaluate for a
Richter’s transformation given his CLL history. The scan showed
hypermetabolic changes in a left hepatic lesion with an standardized
uptake value (SUV) of 10.2; a caudate lobe lesion with an SUVof 11; a
right dome of the liver lesion with an SUV of 8.0; hypermetabolic
bilateral iliac nodes with SUVs of 3.8 and 2.7; and no
fluorodeoxyglucose avidity above blood pool in his supraclavicular,
bilateral axillary, mediastinal, and bilateral perihilar nodes. There was
no evidence of bone marrow infiltration. A liver biopsy was obtained
given it demonstrated the highest uptake value and showedmetastatic
carcinoma that was strongly positive for the prostate-specific
immunohistochemical (IHC) markers NKX3.1 and PSA and
negative for the neuroendocrine markers chromogranin and
synaptophysin (Figure 1).
In light of these findings, the patient was started on leuprolide
22.5 mg plus docetaxel 75 mg/m2. He received six cycles of
docetaxel from March 2020 to June 2020 and tolerated the
treatment well with no major treatment-related side effects
except some mild fatigue. PSA trends shown in Figure 2.
Repeat CT scans after three cycles of docetaxel + ADT showed
stable disease; however, the scans repeated after six cycles
showed disease progression in the liver (Figures 3A, B).
A repeat liver biopsy was again consistent with metastatic
prostatic adenocarcinoma with similar morphology and IHC
profile to the previous biopsy (Figure 4). Molecular testing through
Caris Life Sciences was performed, and it showed positive for
androgen receptor, PTEN loss in exon 2c.164, CDKN1B exon
1p.p92fs, tumor mutation burden (5 mutations/Mb), and stable
microsatellite instability, and negative for NTRK1/2/3, ATM,
BRCA1, BRCA2, FANCA, PALB2, RAD51C, and RAD51D.
Second-line therapy with enzalutamide 160 mg was started in July
2020, but inAugust 2020, he presented to the emergency department
with intractable right upper quadrant pain and CT scans showed
progression of the hepatic masses with small, new infiltrative lesions
(Figure 3C). PSA trends are shown in Figure 2. Due to the rapid
progression, we switched to cabazitaxel 20 mg/m2 with G-CSF as
third-line therapy; the patient received three cycles from September
to October 2020. While on cabazitaxel, his PSA dramatically
increased to 188 ng/ml and repeat scans again demonstrated
worsening of his extensive hepatic metastases (Figure 3D). AR-V7
testing was sent and was negative. We initiated abiraterone acetate
1000 mg daily/prednisone 5 mg twice daily combined with
carboplatin AUC 5 every 3 weeks in November 2020 given PTEN
loss.HealsounderwentY-90embolizationof the right lobeofhis liver
inDecember2020 (Figure3E) anda secondY-90embolizationof the
left lobe of his liver in January 2021 (Figure 3F). Hewas instructed to
continue his abiraterone acetate/prednisone regimen throughout his
Yttrium-90 (Y-90) embolization. Y-90 embolization is a type of
radiation using resin or glass microspheres containing 90Y
administered directly into the hepatic arteries. However, the
carboplatin was held 2 weeks prior and 2 weeks after Y-90
embolization. He received continuous ADT as backbone. He
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tolerated the treatment well without having any major side effects
except grade 2 fatigue and grade 2 nausea/vomiting. His PSA slowly
trended down and became stable, as shown in Figure 2. Repeat CT
scans showed a partial response in the liver. He remains on the same
chemotherapy/hormonal therapy combination at the time of writing
with stable response (Figure 3G).
DISCUSSION
To our knowledge, abiraterone acetate/carboplatin/radiation
combination therapy has never been studied in mCRPC
patients; we report the first case on this chemotherapy/
hormonal therapy/radiation therapy combination. This case
FIGURE 1 | Histopathology of liver biopsy. (A) Metastatic prostate adenocarcinoma displaying significant nuclear enlargement and pleomorphism, prominent nucleoli,
mitotic figures, and comedo-type central necrosis in this representative field. Note the absence in neuroendocrine features and the surrounding benign hepatocytes [H&E
stain, 40× magnification]. (B) Diffuse nuclear positivity with NKX3.1 in tumor cells [NKX3.1 stain, 40× magnification]. (C) Diffuse cytoplasmic positivity with PSA in tumor
cells. (D) No cytoplasmic staining with chromogranin in tumor cells [chromogranin, 40× magnification].
FIGURE 2 | Trends of treatment, prostate serum antigen, and tumor size across patient’s treatment course. *Right inferior lobe lesion and †segment 7 lesion.
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demonstrates the clinical utility of the above combination
therapy in patients with metastatic CRPC with PTEN loss.
Prostate cancer is a heterogenous disease and a small subset of
the prostate adenocarcinoma population can present with
aggressive clinical features like neuroendocrine origin. This
subpopulation frequently carries some driver molecular alterations
in retinoblastoma-associated protein 1 (RB1), tumor protein 53
(TP53), and/or PTEN (22). These alterations have been associated
with abnormal cell proliferation and increased DNA damage
response defects through activation of Akt signaling (23).
Loss of PTEN by mono- and biallelic deletions or mutations is
among the most frequently observed molecular aberrations in
localized and metastatic prostate cancer. PTEN loss is identified in
15%–20% of primary prostate tumor samples (12). Upon
progression to castrate-resistant disease, the incidence increases
to 40%–60% (12). PTEN loss is known to be associated with a poor
prognosis (12). PTEN plays a crucial role as a tumor suppressor in
cell cycle by controlling both G1/S and G2/M transitions (24). Loss
of PTEN promotes activation of the PI3K/AKT/mTOR signaling
pathway, which modulates several downstream pathways. This
signaling pathway also causes abnormal cell proliferation and
survival (25–27). PTEN regulates p53 by modulating its DNA
binding activity. PTEN and p53 both regulate the DNA damage
response pathway by promoting nucleotide excision repair (NER)
following ionizing radiation damage (28). When PTEN function is
lost, Akt signaling pathways are activated through inappropriate
activation of Chk1 (29) and, thus, impairs DNA damage repair
and the DNA damage response pathway (28).
Platinum compounds as monotherapy or combination therapy
have shown promising activity in mCRPC (7, 8). Platinum-based
agents cause mono-, inter-, or intra-strand crosslinking of DNA
triggering DNA damage, which activates ATM/Chk2/p53
signaling, inducing apoptosis and cell cycle arrest (30).
Interestingly, androgen receptor signaling also regulates DNA
repair genes of both non-homologous end joining (NHEJ) and
homologous recombination (HR) repair pathways (31). Preclinical
studies (both in vitro and in vivo models) have demonstrated the
synergistic combinations of radiation and novel androgen
synthesis inhibitors (abiraterone acetate or enzalutamide) in
both androgen-dependent and androgen-independent prostate
cancer (31, 32). The rationale is that the ionizing radiation
enhances DNA damage, which then activates the ATM/Chk2/
p53 signaling pathway promoting cell cycle arrest (33, 34). Anti-
androgen therapy further augments by decreasing DNA repair
genes and, thus, inducing synthetic lethality and causing apoptosis
of prostate cancer cells (31, 35). Recent early-phase studies further
confirmed the clinical efficacy data of these synergistic
combinations (36–38). Phase III studies are ongoing.
We hypothesize that a response was seen in this case because
carboplatin and radiation both induce DNA damage through the
FIGURE 3 | Serial computerized tomography (CT) images of abdomen and pelvis with contrast of the patient’s tumor after sequencing treatments. Green oval
cycles represent tumors. (A) Prior to docetaxel, March 2020. (B) Six cycles after docetaxel, June 2020. (C) Two months after enzalutamide, August 2020. (D) After
three cycles of cabazitaxel, October 2020. (E) After Y-90 embolization to the right lobe of liver concurrent with carboplatin/abiraterone acetate, December 2020.
(F) After Y-90 embolization to the left lobe of liver concurrent with carboplatin/abiraterone acetate, January 2021. (G) On carboplatin/abiraterone acetate, May 2021.
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ATM/Chk2/p53 pathway, and the loss of PTEN activates the
PI3K/AKT pathway and causes DNA damage repair, which is
further augmented by adding anti-androgen therapy. Therefore,
the combination has some synergistic or additive benefits. While
the underlying basic mechanism of our patient’s anti-tumor
response remains uncertain, our case highlights the possible
benefit and safety of combination carboplatin/abiraterone
acetate/radiation in treated mCRPC and suggests that further
prospective studies are warranted to evaluate whether this
combination therapy is effective in this population.
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nuclear enlargement and pleomorphism, prominent nucleoli, mitotic figures, and single-cell necrosis in this representative field. Again, note the absence of
neuroendocrine features [H&E stain, 40× magnification]. (B) Diffuse nuclear positivity with NKX3.1 in tumor cells [NKX3.1 stain, 40× magnification]. (C) Diffuse
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